NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free DBVT Stock Alerts $0.76 -0.03 (-3.80%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.75▼$0.8250-Day Range$0.76▼$0.9352-Week Range$0.65▼$2.37Volume93,434 shsAverage Volume53,123 shsMarket Capitalization$146.57 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get DBV Technologies alerts: Email Address DBV Technologies MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside557.9% Upside$5.00 Price TargetShort InterestHealthy0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 2 Articles This WeekInsider TradingAcquiring Shares$1,624 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.88) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.98 out of 5 starsMedical Sector649th out of 947 stocksBiological Products, Except Diagnostic Industry117th out of 159 stocks 3.2 Analyst's Opinion Consensus RatingDBV Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, DBV Technologies has a forecasted upside of 557.9% from its current price of $0.76.Amount of Analyst CoverageDBV Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of DBV Technologies have been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently increased by 9.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBVT. Previous Next 2.4 News and Social Media Coverage News SentimentDBV Technologies has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DBV Technologies this week, compared to 1 article on an average week.MarketBeat Follows2 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,624.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.71% of the stock of DBV Technologies is held by insiders.Percentage Held by InstitutionsOnly 23.90% of the stock of DBV Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($0.88) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About DBV Technologies Stock (NASDAQ:DBVT)DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Read More DBVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DBVT Stock News HeadlinesMarch 15, 2024 | wsj.comDBV Technologies S.A. ADRMarch 11, 2024 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.comMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial OutcomesMarch 8, 2024 | finance.yahoo.comDBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration DocumentMarch 8, 2024 | globenewswire.comDBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration DocumentMarch 7, 2024 | finance.yahoo.comDBV Technologies SA Reports Decrease in Net Loss and Advances Clinical Programs in Full Year ...March 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 7, 2024 | msn.comDBVT Stock Earnings: DBV Technologies Beats EPS, Beats Revenue for Q4 2023March 7, 2024 | globenewswire.comDBV Technologies Reports Full Year 2023 Financial Results and Business UpdateMarch 4, 2024 | globenewswire.comDBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024February 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising TrialsFebruary 24, 2024 | msn.comDBV Technologies S.A. - Depositary Receipt () (DBVT) Price Target Increased by 15.78% to 2.62February 20, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2024 CongressFebruary 20, 2024 | finance.yahoo.comDBV Technologies to Participate in Upcoming AAAAI 2024 CongressFebruary 20, 2024 | globenewswire.comDBV Technologies to Participate in Upcoming AAAAI 2024 CongressFebruary 13, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Tuesday TradingFebruary 9, 2024 | msn.comDBV Technologies And 2 Other Stocks Under $2 Insiders Are BuyingJanuary 22, 2024 | finance.yahoo.comHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFJanuary 9, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday TradingJanuary 4, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingDecember 4, 2023 | finance.yahoo.comInformation regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023November 27, 2023 | msn.comDown -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)November 22, 2023 | benzinga.comChief Executive Officer at DBV Technologies Acquires Company Stock Options Worth 806,672 SharesNovember 13, 2023 | markets.businessinsider.comPositive EPITOPE Trial Results Bolster Viaskin’s Potential: DBV Technologies SA Receives Buy RatingNovember 9, 2023 | markets.businessinsider.comDBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in ToddlersSee More Headlines Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DBVT CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees104Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$10.00 Low Stock Price Target$1.00 Potential Upside/Downside+549.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,730,000.00 Net Margins-461.32% Pretax Margin-462.35% Return on Equity-46.33% Return on Assets-35.32% Debt Debt-to-Equity RatioN/A Current Ratio4.26 Quick Ratio4.26 Sales & Book Value Annual Sales$15.73 million Price / Sales9.44 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book1.05Miscellaneous Outstanding Shares192,860,000Free Float191,495,000Market Cap$148.50 million OptionableOptionable Beta0.76 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Daniel Tassé (Age 64)CEO & Director Comp: $1.21MDr. Pharis Mohideen (Age 59)Chief Medical Officer Comp: $725.12kMs. Virginie Simone Jeanine Verrechia Boucinha M.B.A. (Age 55)CFO & Principal Accounting Officer Dr. Kevin P. Malobisky M.S.Ph.D., R.A.C., Chief Operations OfficerMs. Michele F. RobertsonChief Legal OfficerMs. Caroline Daniere (Age 49)Chief Human Resources Officer & Chief of Staff Dr. Wence AgbotounouChief Clinical Trial Officer & Senior VPMr. Edward P. Jordan M.B.A. (Age 56)Senior Vice President of Commercial Operations North America Alan KerrSenior VP & Head of Global Regulatory AffairsMr. Pascal WotlingChief External Manufacturing & Supply Chain OfficerMore ExecutivesKey Competitors10X Capital Venture Acquisition Corp. IIINYSE:VCXBVaxartNASDAQ:VXRTGenfitNASDAQ:GNFTSangamo TherapeuticsNASDAQ:SGMOAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Bought 32,405 shares on 3/1/2024Ownership: 0.024%Boxer Capital LLCSold 485,100 shares on 2/15/2024Ownership: 0.259%Citadel Advisors LLCBought 77,861 shares on 2/15/2024Ownership: 0.085%Braidwell LPSold 4,264,500 shares on 2/14/2024Ownership: 4.067%Goldman Sachs Group Inc.Bought 32,405 shares on 2/13/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions DBVT Stock Analysis - Frequently Asked Questions Should I buy or sell DBV Technologies stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DBVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBVT, but not buy additional shares or sell existing shares. View DBVT analyst ratings or view top-rated stocks. What is DBV Technologies' stock price target for 2024? 3 brokerages have issued 1 year price objectives for DBV Technologies' shares. Their DBVT share price targets range from $1.00 to $10.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 557.9% from the stock's current price. View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts. How have DBVT shares performed in 2024? DBV Technologies' stock was trading at $0.9528 on January 1st, 2024. Since then, DBVT shares have decreased by 20.2% and is now trading at $0.76. View the best growth stocks for 2024 here. Are investors shorting DBV Technologies? DBV Technologies saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 584,500 shares, an increase of 9.1% from the February 14th total of 535,800 shares. Based on an average daily volume of 151,400 shares, the short-interest ratio is currently 3.9 days. View DBV Technologies' Short Interest. When is DBV Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our DBVT earnings forecast. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.10. The company had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. DBV Technologies had a negative trailing twelve-month return on equity of 46.33% and a negative net margin of 461.32%. During the same period in the previous year, the firm posted ($0.23) earnings per share. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO). Who are DBV Technologies' major shareholders? DBV Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (4.07%), Boxer Capital LLC (0.26%), Citadel Advisors LLC (0.08%), Cowen AND Company LLC (0.03%), Goldman Sachs Group Inc. (0.02%) and Goldman Sachs Group Inc. (0.02%). Insiders that own company stock include Adora Ndu, Daniel B Soland, Pharis Mohideen and Timothy E Morris. View institutional ownership trends. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DBVT) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.